PURAPHARM (01498) Reports Interim Results with Shareholder Loss of HK$21.81 Million, Up 16.7% Year-on-Year
Stock News
Aug 26
PURAPHARM (01498) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of HK$172 million, representing a 17.02% decrease compared to the same period last year. The loss attributable to owners of the parent company reached HK$21.806 million, an increase of 16.7% year-on-year. Basic loss per share was HK$5.52 cents.
According to the announcement, the revenue decline was primarily attributed to the slowdown in Hong Kong consumption and intense market competition, as well as the group's continued strategy to de-emphasize hospital channels in China's concentrated traditional Chinese medicine formula granules market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.